Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies | Caris Life Sciences
Portal
Order
Home / Research / Publications / Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies

Publications

Back

Concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer show distinct genomic and immunological profiles suggestive of therapeutic strategies

– Caris Life Sciences

Poster

Key Finding:

  • Bladder carcinomas with concurrent truncating mutations in RB1 and CDKN1A have a distinct immunological profile and are enriched for mutations associated with benefit from inhibition of Chk1/Wee1, PARP, and immune checkpoint proteins. 
Read the Full Manuscript Download Publication

Discover
More

  • Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial

    – Caris Life Sciences

    Manuscript

    Abstract We previously reported that tumors harboring any one of four gene mutations (ATM, RB1, FANCC, or ERCC2) were likely to respond to neoadjuvant cisplatin-based… […]

  • S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation

    – Caris Life Sciences

    Poster

    Background We previously reported that MIBC harboring mutations in one or more of ATM , RB1 or FANCC is exquisitely responsive to platinum based NAC,… […]
Learn More

Ready to Get Started on the Journey?

Name(Required)